SPA
CHRS icon

Sherbrooke Park Advisers’s Coherus Oncology CHRS Stock Holding History

Sherbrooke Park Advisers’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-17,527
Closed -$65.6K – 484
2023
Q3 		$65.6K Buy
+17,527
New +$81K 0.02% 478

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's CHRS Position: Q4 2023 in Review

Sherbrooke Park Advisers sold out of Coherus Oncology (CHRS) in Q4 2023, closing a stake of 17,527 shares — an estimated $65.6K sold.

Sherbrooke Park Advisers first reported a position in CHRS in Q3 2023 and held it in 1 quarter. The position peaked at $65.6K in Q3 2023. 156 funds tracked by Wall St. Rank hold CHRS as of Q4 2023.

  • Sherbrooke Park Advisers reported no remaining Coherus Oncology position as of Q4 2023 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 17,527 Coherus Oncology shares in Q4 2023, an estimated $65.6K.
  • Sherbrooke Park Advisers first reported a position in Coherus Oncology in Q3 2023 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Coherus Oncology position peaked at $65.6K in Q3 2023.
  • 156 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2023.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.